Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Ipilimumab, an anti-CTLA-4 antibody, was the first immune checkpoint inhibitor to demonstrate a significantly prolonged overall survival in advanced melanoma, with 2-year survival rates of 20.8%–23.5% [1, 2] and a 10-year survival rate of 21% [3]. However, due to the concerns about immune-related adverse events (irAEs), patients with pre-existing autoimmune disorders have been excluded from clinical trials.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.